Summarized by Masters of Longevity from PR Newswire.
China's NMPA accepted an IND for LET003, an AI‑designed ACVR2A/2B antibody.

Key Takeaways
- The IND covers LET003, an AI‑designed dual ACVR2A/2B antibody.
- Preclinical data showed improved pharmacokinetics and enhanced fat reduction.
- Animal studies found lean mass preservation but human efficacy remains unproven.



